RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A. Chapman, Kwee Yong, Rakesh Popat et al.|Blood|2018Cited by 20
Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)Rakesh Popat, Kwee Yong, James D. Cavenagh et al.|Blood|2014Cited by 1
RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based TherapyJonathan Sive, Michael A. Chapman, John C. Ambrose et al.|Blood|2016Cited by 0